Clinical trials: Medicare
Prostatic Neoplasms, Castration-Resistant
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone…
- Trial name
- NCT05520138
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 5,506 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c
The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of…
- Trial name
- NCT03092882
- Testing
- Diabetes Self-Management Program
- Where
- United States
- Volunteers
- 607 people
- Sponsor
- Evidation Health
Amputation, Amputation; Traumatic, Leg, Lower
Evaluation of Functionality of Amputees According to the Medicare Functional K Classification System
The aim of our study is; To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator…
- Trial name
- NCT06293443
- Testing
- Lower extremity unilateral amputee
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Medipol University
Chronic Myeloid Leukemia (CML)
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
- Trial name
- NCT02363868
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT).
- Trial name
- NCT03127761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Hypertension, Cardiovascular Diseases
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension.
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- SPYRAL CARE (NCT07174622)
- Testing
- Renal Denervation (Symplicity Spyral™)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Medtronic Vascular
Preventive Health Services
Increasing the Feasibility, Impact, and Equity of the Medicare Annual Wellness Visit (AWV)
The goal of this study is to improve the use of preventive health services by implementing a multilevel intervention to stimulate Annual Wellness Visit use in diverse practices across the United States.
- Trial name
- NCT05910736
- Testing
- Medicare AWV Practice Redesign Toolkit
- Where
- 3 sites in United States
- Volunteers
- 22,485 people
- Sponsor
- University of California, Los Angeles
Prostatic Hyperplasia
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Adherence and length of treatment with a 5-alpha reductase inhibitor (5ARI) therapy may be associated with improved clinical outcomes for patients with enlarged prostates (EP) and lower health care related costs.
- Trial name
- NCT01376258
- Testing
- 5ARI
- Volunteers
- 28,903 people
- Sponsor
- GlaxoSmithKline